Commissariat &#xc0; L'&#xc9;nergie Atomique Et Aux &#xc9;nergies Alternatives

Institut National De La Sante Et De La Recherche Medicale

Fabrice Navarro Y Garcia

Jerome Bibette

Jérôme Bibette

Isabelle Texier-Nogues

Mathieu Goutayer

Patrice Marche

Jonathan Bruniaux

Xavier Gidrol

Eric Sulpice

Thomas Courant

Veronique Mourier-Robert

Emilie Bayon

Dorothee Jary

Adrien Nougarede

Dorothée Jary

Véronique Mourier-Robert

A hybrid DNA/RNA molecule, or a complex thereof with at least one nanoparticle, may be used for the prevention or treatment of a disease, in particular a disease of the digestive system.

Hybrid htiRNA/nanoparticle complex and use thereof for treating a disease of the digestive system

The present invention relates to a method for screening a molecule of interest by means of nanoparticles comprising a candidate molecule, a tracer, and a single DNA tag specific to said molecule. The present invention also relates to a method for screening biomarkers of a disease and/or of a phenotype feature, more particularly of a cancer or an infection, by means of said nanoparticles. The invention finally relates to the nanoparticles as such as well as to a library of said nanoparticles.

High-throughput screening method for the identification of biomarkers, therapeutic targets or therapeutic agents

The present invention concerns a method for in vitro or ex vivo transfection of a nucleic acid into a eukaryotic cell in 3D scaffold by contacting eukaryotic cells in 3D scaffold with a formulation in nanoemulsion form which comprises a continuous aqueous phase and a least one dispersed phase, and which comprises said nucleic acid. The invention further relates to a method of screening implementing said method of transfection, and to 3D scaffold comprising eukaryotic cells and said formulation in nanoemulsion form which comprises a continuous aqueous phase and a least one dispersed phase, and which comprises said nucleic acid.

Method for transfection of nucleic acids into eukaryotic cells in 3D scaffold

The present invention relates to a therapeutic agent formulation in the form of a nano-emulsion, comprising a continuous aqueous phase and at least one dispersed oily phase, in which the oily phase comprises further to the therapeutic agent, at least one amphiphilic lipid and at least one solubilizing lipid, and in which the aqueous phase comprises at least one polyalkoxylated cosurfactant. The invention also relates to a preparation method and use of this formulation.

Encapsulation of lipophilic or amphiphilic therapeutic agents in nano-emulsion

The present invention relates to an immunogenic composition comprising a continuous aqueous phase and a dispersed phase as droplets and comprising:

Immunogenic composition in emulsion form

The application relates to an immunogenic composition comprising a continuous aqueous phase and at least two dispersed phases 1 and 2 as droplets, wherein the dispersed phase 1 comprises a surfactant 1 bearing an antigen and the dispersed phase 2 comprises an immunostimulating agent 2, to its preparation method and its uses, notably for producing antibodies, as a drug, as a vaccine or in an immunization method.

Immunogenic composition in emulsion form comprising two dispersed phases, one comprising an antigen and the other comprising an immunostimulating agent

The present invention relates to a formulation of indocyanine green in the form of a nanoemulsion, comprising a continuous aqueous phase and at least one dispersed oily phase, in which the oily phase comprises indocyanine green, at least one amphiphilic lipid and at least one solubilizing lipid. It relates also to a process for the preparation and to the use of the formulation.

Growing community of inventors

Fontaine, France

Fabrice Navarro Y Garcia